





Introduction to LifeWatch

Steve Rietiker, MD, CEO Andy Moore, CFO

Safe Harbor Statement



This communication contains statements that constitute "forward-looking statements". Such forward-looking statements include, without limitation, statements relating to the Company's financial condition, results of operations and business and certain of the Company's strategic plans and objectives. Because these forward-looking statements are subject to risks and uncertainties, actual and / or future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors which are beyond the Company's ability to control or estimate precisely. Examples of such factors include future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors detailed in Company's past and future filings and reports as well as in past and future filings, press releases, reports and other information posted on the Group companies' websites. Readers are cautioned not to put undue reliance on forward-looking statements, which reflect only our opinions as of the date of this presentation. LifeWatch AG disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation does not constitute an offer to sell or a solicitation to purchase any securities of LifeWatch AG. Any such decision must not be made on the basis of the information provided in this presentation.

This presentation must not be distributed in or into the United States of America

LifeWatch Overview



A few significant dates:

- 1993: Incorporated in Israel as Card Guard Scientific Survival Ltd
- 1999: Quoted on the Swiss stock exchange
- 2001: Became a Swiss company (flip-up); Card Guard Scientific Survival Ltd purchases LifeWatch Inc. and Instromedics Inc.
- 2009: Name change to LifeWatch AG

A few significant facts / accomplishments:

- Subsidiaries in the US, India, Japan, Israel, Macedonia and Turkey
- A leader in remote cardiac monitoring services
- January 2014: new Board of Directors and management team
- Turnaround well underway (with a few setbacks)
- April 2016: Board of Directors expanded and capital increase approved
- Legacy legal cases settled in 2016
- Capital increase completed in July 2016

Arrhythmia




- Irregular heartbeat (too fast / too slow)
- > 100 = tachycardia; < 60 = bradycardia
- Affects millions of people (5% of US population)



- Symptoms: palpitations, dizziness, syncope infrequent , frequent or continuous absent (asymptomatic)
- Risks: embolization, stroke, heart failure, sudden cardiac death
- Diagnostic approach: ECG or long-term monitoring (for arrhythmias that happen briefly and unpredictably)
- Treatment: drugs, electricity (cardioversion), defibrillation, pacemaker, electric cautery (ablation), blood thinners (anticoagulation)
- Co-morbidities: stroke, sleep apnea, hypertension, diabetes etc.

LifeWatch's Business Model





Prescription \rightarrow Enrollment \rightarrow Analysis \rightarrow Report \rightarrow Invoice

LifeWatch "Proprietary and Confidential"

Evolution of Cardiac Monitoring Devices



			Ø		Co Hand	Ø	Ch	C Y	Or a	
		Digital holter	King of Hearts Express	MicroER	Explorer	LifeStar AF Express	MCT ACT III	ACT Ex	ACT Elite	MCT 1- Lead Patch
Launch year		-	1994	1996	1999	2001	2008	2009	2012	2016
Discontinuation year		-	2016	2016	-	-	-	-	-	-
Format		Monitor	Monitor	Monitor	Monitor	Monitor	Monitor + gateway	Monitor + gateway	Monitor + gateway	Patch + brain + gateway
Auto- detect	Tachycardia Bradycardia AF	×	×	×	×	~	~	\checkmark	✓	~
	Pause	×	×	×	×	×	\checkmark	√	\checkmark	√
Max recording	g time	48h	5m	6 x 30s	5m	10m		1 month		
Data transmission		Manual upload		Via lar	ndline			Via	GSM	
Data type						ECG				
Auto-detect/auto-send		×	×	×	×	×	\checkmark	\checkmark	✓	✓
Low Frequent	Diagnostic Yield	High Infrequent						Launched	Q3 / 2016 🔺	

September 21, 2016

LifeWatch "Proprietary and Confidential"

Remote Monitoring Solutions INR Self-Test Plus






Patient INR test results delivered wirelessly

Physician views results on INR portal and adjusts doses


Convenient for patient and physician



Remote Monitoring Solutions LifeWatch Deliverable Reports



Presenting Physican				Printingenitie			D.C.			
247	ana a			NUM		- Secon			Second 2	
1	Permary 2.20			50					67 1200	
2 C	Attack 1.8			60					12 (Selic	
6 E	Print og 52, 314		12				22 6500			
	Press og 75 (1974								24 2008	
2	formy 6.8	~		- 9		3.4			22.5.4	
	furstly 5.20			14		84			34244	
	111 BY 6.8			-62		15			212000	
	A			67 67		11%			24 20600	
				e						
1	NUMBER OF A			10					14100	
	12 Carloy 20. 20			12					21,200	
	Start B. B.			64		51 (73		24,0000		
	A			64		12			12 15000	
	A			65		97.			14 1000	
	100 M 1. W					784			14 73/10	
	14.5 My 20. 20	÷.		111				14.24		
e	Ser. av 20.20		79					2.2006		
	Mart 1 2214		60			6%		222/00		
	Sec. 2.114		20			650		27 2560		
a	9449.001		*7			48.6			12 m/m	
6	Math 4 State		80			54			24214	
2	Sect 7 22 C		1.0			84			59 x+18	
14	Vert 1 22 6		66			84			41000	
	Mare 7,0016		60			23			47 22400	
•	344 P 101			æ		800			2 3540	
er 👘	March 10,007			e:					11.01.02	
a i	March 0, 30			10					10.000	
e 2	Minute 2, 20			11		30			66 29496	
8	Mines 2,30			9		**			65.5966	
	Dearen by Duardon	47	Testa	DMC						
C844					Arry rest			1 DEM		
0.411					Mara Haut	Cas.		12		
					new Dev					
5-20 min 1-5 m 1		8			ARGUM	6.000		nia		19-17-2341
iorn Intr					CRIMES'	THOSE .	100		171219	
Core -		141	-	1	- Transa	1 100-12			102-516	



MCT Daily Summary	\bigotimes	MCT as Holter	\bigotimes
MCT Event	\bigotimes	Holter	\bigotimes
MCT Event Meeting MD Criteria	\bigotimes	ARR Event	\bigotimes
MCT End of Service	\bigotimes	ARR End of Service	\bigotimes

September 21, 2016

Legal and Reimbursement Landscape



Reimbursement:


- > 600 managed care contracts with provider networks
- CPT Codes: 93226, 93229, 93271 (Current Procedural Technology)
- CPT Codes cover purely technical work performed by LW
- Ordering physician / cardiologist performs the professional analysis of test results

Relevant laws / guidelines:

- "HIPAA" (Health Insurance Portability and Accountability Act)
- ICD-10-CM Guidelines for Coding and Reporting

Payor Breakdown 2015






Investora Zürich 2016

2015 Business Statistics





LifeWatch "Proprietary and Confidential"

Digital Health: a paradigm shift in healthcare



- Uberification of Healthcare
- Only constant is change
- Change creates opportunities
- Move from traditional fee-for-service to pay-for-performance models (and how much they pay)
- Focus on patient centric vision
- Trend towards wireless devices

LifeWatch is evaluating opportunities and is well positioned to become a player in this space

Key Elements of Strategy



- Transition to a pure play service provider
- Primary focus on revenues from outpatient services in cardiac monitoring and comorbidities
- Increase the demand for the Group's remote cardiac monitoring solutions
- Expand into new markets
- Accelerate growth by pursuing opportunistic strategic acquisitions

LifeWatch's Service Improvements



- Projects nearing completion
 - Updated and more customized web portal
 - Reduction of delivery times for clinical reports
 - More flexible reporting system
 - Fine-tune marketing message and sales management processes
 - More automation via improved algorithms
 - Streamlining of operational processes to reduce the risk of future back-orders

Roadmap to higher growth



- Improve sales management process (US)
- Re-organize marketing (US)
- Align marketing & sales (US)
- Improve efficiency of service offering
- Sell a comprehensive product portfolio incl. patch
- Push INR
- Successful ramp-up in Turkey
- Pursue other promising growth opportunities in the US and Europe





Andy Moore Chief Financial Officer

September 21, 2016

LifeWatch "Proprietary and Confidential"

17

First Half-year 2016 Summary



- First half year 2016 cardiac monitoring revenues up 10.0%
- Overall revenue growth up 8.6% reaching USD 57.0 million versus USD 52.5 million in the first half of 2015
- > Q2 revenue growth slowdown compared to Q1 revenue growth of 12.3%
- EBIT of USD -7.625 million and EBITDA of USD -2.957 million
- Adjusted EBIT and EBITDA of USD 2 million and USD 6.6 million respectively; adjustments made for legal settlements (mainly Highmark and Qui Tam)

Profit & Loss Statement



USD millions	First Half 2016	First Half 2015	2015	+/- in %
Total revenues	57.015	52.512	88.628	8.6%
Total cost of revenues	29.006	-24.765	-51.037	
Gross profit	28.009	27.747	37.591	0.1%
GP margin	49.1%	52.8%	42.4%	
Research & development expenses	-2.706	-1.982	-4.140	36.5%
in % sales	4.7%	3.8%	4.7%	
Selling & marketing expenses	-11.119	-9.453	-18.796	17.6%
in % sales	19.5%	18.0%	21.2%	
General & administrative expenses	-18.055	-12.500	-26.316	44.4%
in % sales	31.7%	23.8%	29.7%	
Legal expenses and other expenses, net	3.754	-	-	
EBIT	-7.625	3.812	-11.661	n.m.
EBIT margin	-13.4%	7.3%	-13.2%	
One-off items *	9.577	-	18.000	
EBIT excluding one-time items	1.952	3.812	6.339	-48.8%
EBIT margin excluding one-time items	3.4%	7.3%	5.9%	
Financial and other income (expenses), net	-0.722	-0.443	-3.956	63%
Tax benefit (expenses)	-0.503	-1.427	4.459	
Share in losses of affiliate company			-0.790	
Result for the period	-9.796	1.942	-11.948	n.m.
EBITDA	-2.957	7.234	-3.620	n.m.
EBITDA margin	-5.2%	13.8%	-4.0%	
EBITDA excluding one-time items	6.620	7.234	14.370	-8.5%
EBITDA margin excluding one-time items	11.6%	13.8%	13.5%	

September 21, 2016

LifeWatch "Proprietary and Confidential"

Adjusted numbers

LifeWatch®

One-time items (in USD million):	
Vital Signs Patch development / inventory	-3.612
Qui Tam settlement	-12.975
Reduction in Highmark settlement	8.973
Pharmalife recovery net of employee settlement	0.248
Professional fees related to legal settlements	-0.964
Automation of bad debt provision calculation	-1.247
Total	-9.577
Adjusted EBIT	1.952
Adjusted EBIT margin	3.4%
Adjusted EBITDA	6.620
Adjusted EBITDA margin	11.6%

Review of Operating Expenses



- Series Serie
- Higher R&D costs due to a reduction in capitalization in H1 2016 and higher labor and external contractor costs. USD 672 million capitalized in R&D in the first half of 2016 versus USD 1.0 million in the first half of 2015.
- Higher S&M expenses at 19.5% of sales versus 18% of sales in the first half of 2015.
 The increase is attribute to higher sales commission payments for the strong revenue growth in the first quarter of 2016.
- Higher G&A expenses at 31.7% of revenues versus 23.8% of revenues in the first half of 2015. The large increase in G&A expenses was caused by two large one-time items for legal costs and the automation of the bad debt provision calculation totaling \$2.2 million as well as higher labor, regulatory and IT costs. In particular a new disaster recovery system was installed, internet connectivity was upgraded, a new website is being developed, a global bonus system was implemented and HR and FDA consultants were used.
- Legal settlements totaling USD 3.8 million were recorded in the first half of 2016. This includes a provision for the Qui Tam settlement of USD 12.98 million, offset by a reduction in the Highmark settlement of USD 8.97 million and a recovery from the Pharmalife case of USD 248 thousand, net of an employee settlement. There were no such costs in the first half of 2015.

Balance Sheet



USD millions	June 30. 2016	June 30. 2015	+/- in USD million
Balance sheet total	76.317	71.939	4.378
Cash and cash equivalents	3.497	7.108	-3.611
Net working capital (NWC)	-24.715	5.450	-30.165
NWC in % of revenues	n.m.	10.4%	
Property, plant & equipment, net	16.580	16.224	3.199
Goodwill & intangibles	18.861	17.335	1.778
Provisions	23.225	6.059	17.166
Interest-bearing debt	11.497	6.702	4.795
Net cash	-8.000	0.406	-8.406
Equity	15.886	39.036	4.221
Equity Ratio	20.8%	54.3%	

Cash Flow Statement



USD millions	June 30. 2016	June 30. 2015	+/- in USD million
Net cash from operating activities	0.889	4.188	6.967
Net cash from investing activities	-5.130	-5.737	-2.834
Net cash from financial activities	0.338	1.570	-0.105
Increase (decrease) in cash and cash equivalents	-3.903	0.021	3.937
Balance of cash and cash equivalents at beginning of period	7.400	7.087	-3.049
Balance of cash and cash equivalents at end of period	3.497	7.108	0.888

Summary and Outlook



- Disappointing first half of the year
- With the resolution of the Highmark and Qui Tam legal cases the Company has resolved the remaining historical issues and can now fully focus on growing the business going forward
- Successful capital increase completed in July 2016 and yielding CHF 43.7 million net of costs
- Ramping-up of Mobile Cardiac Telemetry (MCT) 1-lead patch production
- Several internal development projects to improve service and efficiency nearing completion
- Controlled entry to the Turkish market planned in Q1 2017
- Foundations for future growth have been laid and the benefits will materialize in 2017 and beyond

Thank you for your interest!



Our experience and credentials let you take care of your life.



Back-up Slides

LifeWatch "Proprietary and Confidential"

LifeWatch Services Remote Monitoring Solutions





September 21, 2016

LifeWatch "Proprietary and Confidential"

Remote Monitoring Solutions MCT 1-Lead Patch

Up to 30 days of retrievable ECG data

QRS detection and extraction

Analysis of R-R intervals and P-wave recognition Heart Rate histogram correlated to AFib, symptoms and activities

Captures AFib onset and offset Daily Summary, End of Session and Physician Notification reports with AF Burden, average heart rate and patient compliance

Full disclosure report on demand





Remote Monitoring Solutions Holter Plus Extended MCT





Convenient conversion of service from 24/48 hour Holter to ambulatory cardiac telemetry for up to 30 days

Comprehensive Holter report with quantification of heart rates and all arrhythmia types

Periodic ECG samples, including onset and offset of arrhythmia episodes

Automated QT and ST segment measurements

Automated HRV measurement

Accurate AF Burden

Remote Monitoring Solutions MCT Elite



Automatic conversion from MCT III device to standard cardiac event monitor with auto trigger and auto send capabilities

3-channel EKG for more specific and sensitive diagnostic value

Auto detect / auto-send of symptomatic and asymptomatic Atrial Fibrillation, Bradycardia, Tachycardia and Pause

Manual event button for symptomatic episodes





Remote Monitoring Solutions DigiTrak XT Holter Monitor

Captures every heartbeat and can document arrhythmia onset and offset of AF, Bradycardia, Tachycardia and Pause

Standard 24 hours of memory

Flash memory technology

ECG view from 5-lead cable

EASI derived 12-lead

Constant diagnostic 3-channel lead ECG

Automatic uploading





September 21, 2016

Remote Monitoring Solutions Cardiac Event Monitors



Explorer™

Manual trigger

1-lead ECG

5 minutes of looping memory captures ECG both before and after patient pushes button record event

Patient manually transmits data with a landline telephone



LifeStar AF Express™

Auto-trigger

1-lead ECG

Records 45 seconds presymptom and 15 seconds post trigger

10 minutes of memory

Patient transmits recordings by landline telephone

